mitotane has been researched along with purvalanol a in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Amendola, D; Brunetti, E; Bucci, B; Cerquetti, L; De Paula, U; Marchese, R; Misiti, S; Raza, G; Sampaoli, C; Stigliano, A; Toscano, V | 1 |
2 other study(ies) available for mitotane and purvalanol a
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Cell Proliferation; Cyclin B; Cyclin-Dependent Kinases; DNA Mismatch Repair; DNA Repair Enzymes; Drug Evaluation, Preclinical; G2 Phase; Humans; Mitotane; Multiprotein Complexes; Protein Kinase Inhibitors; Purines; Radiation-Sensitizing Agents; Radiation, Ionizing; Tumor Cells, Cultured | 2010 |